2022 World Conference on Lung Cancer (ePosters)-EP08.02-106. KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations

EP08.02-106. KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations

Back to course

Pdf Summary

A study conducted by researchers from the University of Cologne and other institutions aimed to determine the prognostic value of a KEAP1/NFE2L2 pathway signature in predicting the survival of non-small cell lung cancer (NSCLC) patients without actionable driver mutations. Mutations in KEAP1 and NFE2L2 have been associated with poor outcomes in NSCLC patients, regardless of the treatment method. However, it is not known if all mutations have the same functional impact.<br /><br />The researchers developed a KEAP1/NFE2L2 pathway signature that could accurately predict functional mutations in NSCLC patients with KEAP1/NFE2L2 mutations. They then compared a cohort with KEAP1/NFE2L2 mutations to a control cohort without known targetable driver mutations to determine the prognostic value of the signature. Both cohorts consisted of NSCLC patients identified between 2015 and 2018, with biopsy samples available for next-generation sequencing.<br /><br />The researchers focused on overall survival (OS) as the primary outcome measure and used Kaplan-Meier statistics to analyze the results. The analysis showed that the KEAP1/NFE2L2 transcriptomic signature outperformed mutational status in identifying patients with a poor prognosis.<br /><br />The researchers observed that the median OS in the KEAP1/NFE2L2 cohort was 7.2 months compared to 5.4 months in the control cohort, although this difference was not statistically significant. However, when considering specific subgroups within the KEAP1/NFE2L2 cohort, they found that patients with a specific mutation had worse outcomes.<br /><br />In conclusion, the study demonstrated that the KEAP1/NFE2L2 transcriptomic signature was better than mutational status in predicting the prognosis of NSCLC patients. The findings suggest that this signature could be a valuable tool in identifying patients with a poor prognosis and may guide treatment decisions in advanced-stage NSCLC patients without actionable driver mutations.

Asset Subtitle

Matthias Scheffler

Meta Tag

Speaker Matthias Scheffler

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

KEAP1/NFE2L2 pathway signature

prognostic value

non-small cell lung cancer

NSCLC patients

actionable driver mutations

KEAP1 mutations

NFE2L2 mutations

functional impact

transcriptomic signature

overall survival